Contents
Editor’s Letter
Editor’s introduction to the initial issue of the third volume of GaBI Journal
Editorial
Drug shortages hit US oncologists hard
Letters to the Editor
Commentary
Biosimilar monoclonal antibodies approved for use in the EU
The biosimilar name debate: what’s at stake for public health
Original Research
Alternative statistical strategies for biosimilar drug development
Review Article
Statistical considerations for the development of biosimilar products
Perspective
Guidelines
New product-specific bioequivalence guidance
Meeting Report
Special Report
Analysis of European policy towards generic medicines
Regulatory
Comparison of biosimilars guidelines
Abstracted Scientific Content
Biosimilarity of anticancer monoclonal antibodies in the clinic
Sponsored Article
Biosimilar monoclonal antibodies development simplified